ShinecoSISI
SISI
About: Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
Employees: 119
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
33% more funds holding
Funds holding: 3 [Q2] → 4 (+1) [Q3]
12% more capital invested
Capital invested by funds: $29.6K [Q2] → $33K (+$3.42K) [Q3]
0.32% more ownership
Funds ownership: 0.18% [Q2] → 0.49% (+0.32%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for SISI.
Financial journalist opinion
Neutral
PRNewsWire
4 months ago
Future FinTech Announces the Appointment of Hu Li as the New CEO
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024.
Neutral
GlobeNewsWire
5 months ago
Shineco Announces Closing of $2 Million Underwritten Public Offering
Beijing, July 15, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the closing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any.
Negative
InvestorPlace
5 months ago
Why Is Shineco (SISI) Stock Down 54% Today?
Shineco (NASDAQ: SISI ) stock is falling hard on Friday after the agricultural produce company announced the pricing of a public offering for its shares. This public offering has Shineco selling 1,869,160 shares of SISI stock for $1.07 each.
Neutral
GlobeNewsWire
5 months ago
Shineco Announces Pricing of $2 Million Underwritten Public Offering
Beijing, July 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the pricing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on July 15, 2024, subject to satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
5 months ago
Shineco Announces Proposed Underwritten Public Offering
Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
5 months ago
Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement
BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for the period of 10 consecutive business days, from May 20, 2024 through June 4, 2024, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and advised that this matter is now closed.
Neutral
GlobeNewsWire
5 months ago
Shineco, Inc. Announces Entering into a Securities Purchase Agreement with Gross Proceeds of $7.0 Million
BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non-U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchasers in a private placement financing transaction (the “Offering”) at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000, before the deduction of customary expenses. The Purchasers are a former related party of the Company, who agreed to purchase 1,000,000 shares of common stock, a management member of the Company, who agreed to purchase 200,000 shares of common stock, and an individual investor who agreed to purchase 200,000 shares of common stock. The Offering is expected to close, and the Shares are expected to be issued, on or about July 31, 2024.
Neutral
GlobeNewsWire
6 months ago
Shineco Enters into a Letter of Intent with Meitong Technology to Address China's Aging Population
BEIJING, June 20, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDA: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 18, 2024, it entered into an Investment Letter of Intent (the “Investment LOI”) with Beijing Oriental Meitong Technology Co., Ltd. (“Meitong Technology”) whereby Shineco intends to invest $20 million in Meitong Technology in exchange for 80% of Meitong Technology's shares. The Company believes that the acquisition of equity in Meitong Technology will add to the Company's core competencies and result in operating synergies that will enhance the Company's value proposition.
Neutral
GlobeNewsWire
6 months ago
Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products
Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology (Jiangsu) Co., Ltd. (“Shangkang Life Science”) entered into a Strategic Cooperation Framework Agreement (“the Agreement”) with Turing Video (Shenzhen) Co., Ltd (“Turing Video”) to jointly develop a series of smart medical products and introduce their biotechnology and other innovative health solutions to the healthcare market.
Neutral
PRNewsWire
7 months ago
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING , May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd.
Charts implemented using Lightweight Charts™